The pharmacodynamic features of Warfarin (very long: onset of action, elimination half-life, duration of action, time to steady-state concentration) are the cause for the switching problems. All three new anticoagulants have more similar and shorter time to steady-state concentrations and other parameters. Although I didn't see protocols for management of transitions from one to another (just to LMWH and/or Warfarin), I think it will be prety straightforward.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.